Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a presentation by CEO Joseph C. Papa and CFO Paul S. Herendeen at the virtual 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. The presentation focuses on the company's business recovery post-COVID-19 and updates on its plan to spin off the eye health business. The presentation details are available on Bausch Health's Investor Relations page. Bausch Health aims to enhance global health through its pharmaceutical and medical products.
The Bausch Foundation, overseen by Bausch Health (BHC), released its inaugural activity report detailing philanthropy initiatives from late 2017 to June 30, 2020. The Foundation aims to enhance patient lives globally by providing access to essential medicines and supporting healthcare education. Notably, Bausch Health donated approximately $600 million in pharmaceutical products in 2018 and 2019 to aid financially struggling patients. The Foundation focuses on disease prevention, improving patient outcomes, education, and global relief efforts.
Bausch Health Companies will participate in the 18th Annual Morgan Stanley Global Healthcare Conference on Sept. 16, 2020, at 1:15 p.m. ET. Key executives, including Joseph C. Papa (Chairman and CEO), Sam Eldessouky (SVP), and Arthur J. Shannon (SVP of Investor Relations), will present. Investors can access a live webcast and audio archive on the company’s Investor Relations page. Bausch Health focuses on pharmaceuticals, medical devices, and over-the-counter products, particularly in eye health, gastroenterology, and dermatology.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced on August 31, 2020, a plan to reduce its debt by $100 million through the redemption of senior notes. The company will redeem $100 million of its 5.875% Senior Notes due September 30, 2020, using cash generated from operations. An irrevocable notice of redemption will be issued to the record holders of these notes. Bausch Health aims to strengthen its financial position and continues to focus on advancing global health through its healthcare products.
Bausch Health's subsidiary, Bausch + Lomb, has received approval from Australia's Therapeutic Goods Administration (TGA) for the BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses. This product is expected to be available to select practitioners in Australia by Q4 2020, with a nationwide launch planned for early 2021. This approval complements Bausch + Lomb's existing contact lens offerings and aligns with the company’s expansion strategy, which includes launches in Japan and the United States, as well as further expansions in Canada and Hong Kong.
Bausch + Lomb has launched the INFUSE™ silicone hydrogel daily disposable contact lens, designed to combat contact lens dryness affecting about half of U.S. lens wearers. This lens utilizes ProBalance Technology™ to maintain ocular surface homeostasis and retain 96% moisture for 16 hours. The advanced design aims to provide comfort without sacrificing vision correction. Bausch Health Companies Inc. (NYSE/TSX: BHC) emphasizes its commitment to innovative eye care solutions, reflecting the need for advanced materials in contact lens technology.
Bausch Health announced the approval of BAUSCH + LOMB ULTRA® ONE DAY daily disposable silicone hydrogel contact lenses by Health Canada. These lenses incorporate Advanced MoistureSeal® Technology and ComfortFeel Technology, ensuring a high level of comfort and eye health for up to 16 hours. They will be available to select practitioners in Canada starting Q4 2020, with a full launch expected in early 2021. This innovation enhances Bausch + Lomb's existing product portfolio, aiming to improve patient experience in eye care.
Bausch Health reported revenues of $1.664 billion for Q2 2020, a 23% decline from Q2 2019, largely due to the COVID-19 pandemic.
GAAP net loss was $326 million, compared to a $171 million loss in the same quarter last year.
The company has narrowed its full-year revenue guidance to $7.80 - $8.00 billion and Adjusted EBITDA to $3.15 - $3.30 billion.
Despite challenges, Bausch Health is focused on market share growth and launching new products.
Bausch Health Companies Inc. (BHC) announced its plan to spin off its eye health business, creating an independent entity named Bausch + Lomb - NewCo. This strategic move aims to enhance focus on two distinct business segments: a dedicated eye health company and a diversified pharmaceutical firm specializing in gastroenterology, aesthetics/dermatology, and neurology. The spinoff is expected to improve financial transparency and unlock shareholder value. Bausch + Lomb - NewCo reported $3.7 billion in revenue for 2019, while BHC's revenue was $4.9 billion, with plans to report separate financials starting Q1 2021.
Bausch Health (NYSE/TSX: BHC) has resolved a legacy investigation by the SEC concerning its past relationship with Philidor Rx and certain accounting practices from 2014-2015. The settlement, which involves a $45 million civil penalty for negligence-based charges, resolves all SEC claims without admission of guilt. The company has undergone significant management changes, with a new Board of Directors credited for remedial actions. CEO Joseph C. Papa emphasized that this resolution is a crucial step in the company's transformation.